The future outlook for Compugen Ltd. (CGEN) is closely tied to the clinical progress of its oncology pipeline, specifically key trials like the MAIA study evaluating COM701. Wall Street equity research analysts maintain a consensus Strong Buy rating on the stock, supported by a median twelve-month price target ranging between $4.00 and $6.00 per share. Additionally, the company has successfully extended its financial cash runway to support operations well into future years, mitigating near-term dilution risks while continuing to advance valuable partnership milestones with major global pharmaceutical collaborators.